Can a smart drug deliver a lethal payload to endometrial cancer?
NCT ID NCT07743541
First seen Aug 04, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tests an experimental drug called TUB-040 in people with recurrent or progressive endometrial cancer that has not responded to platinum-based chemotherapy and immunotherapy. TUB-040 is an antibody-drug conjugate designed to bind to a protein called NaPi2B on cancer cells and deliver a toxic agent directly to them. The trial has two phases: the first aims to find the safest dose and check tolerability, while the second evaluates how well the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TUB-040, an antibody-drug conjugate that targets NaPi2B on cancer cells to deliver a toxic payload
- What this could lead to
- If successful, TUB-040 could offer a new treatment option for people with recurrent endometrial cancer who have run out of standard options.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or may cause significant side effects. The results are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
START Los Angeles
Los Angeles, California, 90025, United States
-
START Mountain Region, LLC
West Valley City, Utah, 84119, United States
-
START New Jersey
East Brunswick, New Jersey, 08816, United States
-
START New York-Long Island
Lake Success, New York, 11042, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.